A study of danazol's safety.

S S Jick; Susan S. Jick; Michael W. Myers; M W Myers

A study of danazol's safety.

S S Jick, Susan S. Jick, Michael W. Myers, M W Myers

Pharmacotherapy · 1996 · vol. 15(6) , pp. 740–1 · PMID:8602381 · W1589869025

article OA: closed CC0 ⤵ 1 in-corpus citation

View on OpenAlex View on PubMed

Abstract

In a review of medical records of 530 recipients of danazol at Group Health Cooperative of Puget Sound, we identified 154 (29%) people who reported at least one adverse event that occurred within 45 days after receiving the drug. In no patient did the event require hospitalization, and there were no known long-term sequelae.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Estrogen Antagonists Adult Danazol Drug Eruptions Drug Eruptions Endometriosis Endometriosis Estrogen Antagonists Female Fibrocystic Breast Disease Fibrocystic Breast Disease Humans Male Retrospective Studies

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Rapidly Progressive Pulmonary Fibrosis in a Patient Treated with Danazol for Idiopathic Thrombocytopenic Purpura 2004

Cited by (1)

Rapidly Progressive Pulmonary Fibrosis in a Patient Treated with Danazol for Idiopathic Thrombocytopenic Purpura 2004

Source provenance

europepmc: last seen: 2026-06-16T06:07:01.518242+00:00
openalex: last seen: 2026-05-11T04:23:31.979020+00:00
pubmed: last seen: 2026-05-13T22:11:08.331550+00:00

License: CC0 · commercial use OK